CSPC Hunan Jingfeng Pharmaceutical Co., Ltd. (SHE:000908)
China · Delayed Price · Currency is CNY 6.19
-0.05 (-0.80%)
Sep 14, 2026, 3:04 PM CST
SHE:000908 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
| 10,980 | 6,326 | 4,302 | 2,850 | 2,798 | 3,836 | |
Market Cap Growth | 111.17% | 47.03% | 50.93% | 1.89% | -27.06% | -3.96% |
Enterprise Value | 9,276 | 6,503 | 4,767 | 3,316 | 3,367 | 5,039 |
Last Close Price | 6.24 | 7.19 | 4.89 | 3.24 | 3.18 | 4.36 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | - | - | 28.25 | - | - | - |
Forward PE | - | 15.36 | 15.36 | 15.36 | 15.36 | 15.36 |
PS Ratio | 27.65 | 16.73 | 10.34 | 4.34 | 3.33 | 4.73 |
PB Ratio | 5.40 | -223.93 | -284.36 | -16.32 | 13.88 | 11.70 |
P/TBV Ratio | 5.41 | - | 152.38 | - | 92.95 | 22.19 |
P/FCF Ratio | - | 115.53 | - | 115.67 | 25.49 | 44.75 |
P/OCF Ratio | - | 106.63 | - | 81.29 | 22.70 | 30.98 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 23.36 | 17.20 | 11.46 | 5.05 | 4.01 | 6.21 |
EV/EBITDA Ratio | - | - | 226.73 | - | 104.46 | - |
EV/FCF Ratio | - | 118.77 | - | 134.56 | 30.68 | 58.79 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 0.00 | -3.30 | -31.11 | -3.40 | 2.97 | 2.67 |
Debt / EBITDA Ratio | - | - | 20.10 | - | 16.65 | - |
Debt / FCF Ratio | - | 1.70 | - | 24.10 | 5.46 | 10.19 |
Net Debt / Equity Ratio | -0.81 | -0.63 | -25.46 | -3.32 | 2.07 | 2.14 |
Net Debt / EBITDA Ratio | 192.88 | -1.00 | 18.32 | -8.88 | 12.95 | -3.30 |
Net Debt / FCF Ratio | 13.61 | 0.32 | -55.57 | 23.56 | 3.80 | 8.18 |
Asset Turnover | 0.24 | 0.43 | 0.42 | 0.52 | 0.52 | 0.36 |
Inventory Turnover | 3.20 | 3.64 | 2.85 | 2.14 | 1.49 | 1.67 |
Quick Ratio | 4.85 | 0.28 | 0.19 | 0.13 | 0.37 | 0.35 |
Current Ratio | 5.04 | 0.34 | 0.25 | 0.21 | 0.53 | 0.50 |
Return on Equity (ROE) | -3.90% | - | - | -1685.13% | -35.99% | -41.75% |
Return on Assets (ROA) | -1.30% | -3.31% | -0.33% | -5.18% | -0.75% | -8.64% |
Return on Invested Capital (ROIC) | -9.04% | -173.54% | -19.06% | -32.73% | -2.36% | -21.89% |
Return on Capital Employed (ROCE) | -1.70% | -253.10% | -15.10% | -555.10% | -5.20% | -71.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 11, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Earnings Yield | -0.39% | -1.28% | 3.54% | -8.28% | -4.38% | -4.27% |
FCF Yield | -1.10% | 0.87% | -0.16% | 0.86% | 3.92% | 2.23% |
Payout Ratio | - | - | 8.80% | - | - | - |
Buyback Yield / Dilution | -29.34% | -0.04% | -0.02% | 0.02% | 0.01% | 0.36% |
Total Shareholder Return | -29.34% | -0.04% | -0.02% | 0.02% | 0.01% | 0.36% |